Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus LOCAMETZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus LOCAMETZ.
ALA-CORT vs LOCAMETZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Metformin hydrochloride is a biguanide antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes mellitus. It primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Locametz (gallium Ga 68 gozetotide) is administered intravenously at a dose of 3-5 mCi (110-185 MBq) as a single injection for PET imaging. No repeated dosing schedule is defined.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life of 14 hours (range 12-16 h); clinically, steady-state achieved after 3 days.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal excretion (70% unchanged), with 20% fecal elimination via biliary secretion; 10% metabolized.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid